Evaluation for effect of SGLT2 inhibitor on postprandial hyperglycemia and cardiac function in diabetic patients with coronary artery disease

Evaluation for effect of SGLT2 inhibitor on postprandial hyperglycemia and cardiac function in diabetic patients with coronary artery disease - Evaluation for effect of SGLT2 inhibitor on postprandial hyperglycemia and cardiac function in diabetic patients with coronary artery disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031549

Enrollment

Registered

2018-03-05

Start date

2018-03-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease, Diabetes

Interventions

Tofogliflozin 20mg once daily for 12 weeks in the SGLT2 inhibitor group Standard therapy for 12 weeks in the control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients provided written informed consent 2.Patients with history of coronary intervention. 3.Patients with diabetes treated with HbA1c < 7.0%

Exclusion criteria

Exclusion criteria: 1.Patients who have already taken SGLT2 inhibitor 2.Patients with drug allergy of SGLT2 inhibitor 3.Patients with history of anteroseptal myocardial infarction 4.Patients had received hemodialysis 5.Creatinine Clearance < 30 ml/min 6.Patients with contraindication of MRI 7.Patients who judged as ineligible clinical staffs

Design outcomes

Primary

Measure	Time frame
Changes of postprandial hyperglycemia after administration SGLT 2 inhibitor for 12 weeks	—

Secondary

Measure	Time frame
Changes of cardiac function and myocardial triglyceride content after administration SGLT 2 inhibitor for 12 weeks	—

Countries

Japan

Contacts

Public ContactMakoto Hiki

Juntendo University Graduate School of Medicine Department of Cardiovascular Medicine

m-hiki@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026